Clinical Trials Browser

Approved for marketing × INDUSTRY × Paraganglioma × Clear all

NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Approved for marketing

Paraganglioma, Pheochromocytoma